CD8α Coreceptor to Improve TCR Gene Transfer to Treat Melanome: Down-Regulation of Tumor-Specific Production of IL-4, IL-5 and IL-10 by Willemsen, R.A. (Ralph)
CD8 Coreceptor to Improve TCR Gene Transfer to Treat
Melanoma: Down-Regulation of Tumor-Specific Production of
IL-4, IL-5, and IL-10
Ralph A. Willemsen,1 Zsolt Sebestye´n,1 Cees Ronteltap, Cor Berrevoets, Joost Drexhage, and
Reno Debets2
Therapeutic success of TCR gene transfer to treat tumors depends on the ability of redirected T cells to become activated upon
tumor recognition in vivo. Help provided by tumor-specific Th1 cells is reported to relieve T cells from an anergized state and to
induce tumor regression. We recently demonstrated the ability to generate melanoma-specific Th1 cells by genetic introduction of
both a CD8-dependent TCR and the CD8 coreceptor into CD4 T cells. In this study, we analyzed a TCR that binds Ag
independently of CD8, a property generally preferred to induce tumor-specific T cell responses, and addressed the contribution
of CD8 following introduction into TCR-transduced CD4 T cells. To this end, primary human CD4 T cells were gene
transferred with a high-avidity TCR, and were shown not only to bind peptide/MHC class I, but also to effectively kill Ag-positive
tumor cells in the absence of CD8. The introduction of CD8 up-regulates the tumor-specific production of TNF- and IL-2 to
some extent, but significantly down-regulates production of IL-4, IL-5, and IL-10 in CD4 T cells. The introduction of a mutated
cysteine motif in CD8, which prevents its binding to LCK and linker for activation of T cells, did not adversely affect expression
and T cell cytotoxicity, but counteracted the CD8-mediated down-regulation of IL-4 and IL-5, but not IL-10. In conclusion,
CD8 down-regulates the production of major Th2-type cytokines, in part mediated by LCK and/or linker for activation of T cells,
and may induce differentiation of tumor-specific Th1 cells, which makes this coreceptor an interesting candidate to improve the
clinical potential of TCR gene transfer to treat cancer. The Journal of Immunology, 2006, 177: 991–998.
T o initiate effective and persistent control of tumor growthby specific T cells, it is necessary that T cells continue toproliferate in vivo, repopulate the host, and enter the
memory compartment. Adoptive transfer of Ag-specific T cells has
recently shown therapeutic successes in the eradication of tumors
in patients with metastatic melanoma (1, 2), and the treatment of
EBV and CMV infections in stem cell and organ transplant pa-
tients (3–5). However, ex vivo expanded CD8 T cells do gener-
ally not persist beyond a few days after infusion into patients and
are prevented from replicating or even functioning in vivo. The
compromised antitumor efficacy of transferred CD8 T cells is
thought to be a consequence of the tumor’s inability to efficiently
activate tumor-specific T cells due to significant immunosuppres-
sion and defective Th cell function (6, 7).
The administration of CD4 Th cells concurrently with CD8
T cells may prevent exhaustion of infused CD8 T cells (8, 9) and
result in effective antitumor T cell responses (10). It has been well
documented that CD4 T cells activate dendritic cells, thereby
providing enhanced Ag presentation and costimulation via cross-
linking of CD40, which leads to priming of Ag-specific CD8
CTL function (11). In fact, adoptive transfer of CD4 T cells
results in de novo generation of Ag-specific CD8 T cells and
concomitant tumor destruction (12). Furthermore, CD4 T cells
activate CD8 T cells that are already present at the site of the
tumor and enable them to traffic to and/or remain within the tumor
(8), activate other immune cells, and induce an antitumor humoral
response, and are a major source of IFN-, an effector cytokine
with potent tumor-regressing activity via inhibition of tumor-in-
duced angiogenesis (13) and the ability to activate tumor-infiltrat-
ing macrophages (14).
We explored the use of human CD4 T cells for antitumor
therapy, and demonstrated that CD4 T cells can be redirected to
MAGE-A1 Ag presented by HLA-A1 molecules on melanoma
cells via TCR gene transfer, and that triggering of MAGE-A1/
HLA-A1-specific immune responses, such as Ag-specific cytotox-
icity and Th1-type cytokine production, required cointroduction of
the CD8 coreceptor (15). A genetic strategy to induce Th1 dif-
ferentiation of tumor-specific T cells such as genetic introduction
of CD8 may prove relevant for TCR gene therapy because tumor-
specific Th1 cells have been reported to induce potent and persis-
tent tumor regression (12, 16).
Human CD8 is a heterodimeric protein consisting of an - and
-chain, each 33 kDa, and is expressed on most thymocytes and
about one-third of peripheral blood T cells, with a small portion of
T cells expressing both CD8 and CD8 dimers. Recent crys-
tallographic data of human CD8 Ig-like domain and HLA-A2
show that one CD8 homodimer binds one MHC molecule in a
manner similar to Ab-Ag binding (17), and that CD8 binding in-
volves contact to the 2-microglobulin, 2, and 3 domains of the
peptide/MHC complex (the latter being the major binding do-
main). Importantly, structural data indicate that the binding of
CD8 to peptide/MHC does not cause any significant changes to
the TCR-binding platform of the peptide/MHC, and ensure that the
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specificity for the peptide/MHC is determined and dominated by
the TCR. Interestingly, the binding of CD8 to peptide/MHC, when
compared with the binding of TCR to peptide/MHC, is weak, but
shows extremely fast kinetics (18, 19). Given the low binding af-
finity of CD8 for peptide/MHC, it is remarkable that inhibition
of this interaction, either via soluble CD8 or via membrane ex-
pressed and mutated MHC class I (to adversely affect the CD8:
peptide/MHC interaction), clearly reduces T cell activation and
target cell lysis by CTLs (20–22). To mediate T cell activation,
CD8 gets recruited to the peptide/MHC:TCR complex, which en-
ables the CD8-chain-associated LCK to phosphorylate CD3.
Phosphorylation of CD3 is followed by (recruitment and) phos-
phorylation of ZAP-70 and linker for activation of T cells (LAT),3
the latter of which also associates with CD8 to get in close prox-
imity of the TCR, where it bridges proximal to more distal TCR
signaling (23).
TCR that bind Ag independently of CD8’s ability to struc-
turally stabilize the TCR:peptide/MHC interaction are generally
preferred to generate tumor-specific CD4 Th cells following gene
transfer (24). In this study, we therefore addressed the contribution
of CD8 to CD4 T cell responses following redirection with a
CD8-independent TCR. To this end, CD4 T cells were trans-
duced with genes encoding a high-affinity gp100/HLA-A2-specific
TCR, which enabled them to bind the corresponding peptide/
MHC class I ligand and exert gp100-specific cytotoxicity indepen-
dent of CD8. However, the introduction of CD8 significantly
down-regulates the Ag-specific production of IL-4, IL-5, and
IL-10 in T cells that, except for IL-10, depends on recruitment of
LCK and/or LAT. The CD8-induced bias of a tumor-specific T
cell response toward a Th1-type T cell response may counteract
the immune-suppressed status of tumor-bearing hosts and improve
clinical TCR gene transfer to treat cancers.
Materials and Methods
Cells and reagents
PBL from healthy donors were obtained after approval by the Erasmus
Medisch Centrum Medical Ethical Committee, and isolated and expanded,
as described elsewhere (25). The melanoma cell lines BLM (HLA-
A2positive), BLM transfected with human gp100-encoding cDNA
(BLMgp100), and FM3 (gp100/HLA-A2positive, a gift from J. Zeuthen,
Copenhagen, Denmark) were cultured, as described previously (26). The
culture conditions for the melanoma cell line MZ2-MEL3.0 (MAGE-A1/
HLA-A1positive, a gift from P. Coulie, Brussels, Belgium) are described
previously (27). The human embryonic kidney cell line 293T and the am-
photropic packaging cell line Phoenix were grown in DMEM (Invitrogen
Life Technologies) supplemented with 10% bovine calf serum (HyClone)
and used to package retroviruses carrying RNA encoding TCR and/or
CD8. K562, a chronic myelogenous leukemia cell line, was cultured in
RPMI 1640 medium supplemented with 200 mM L-glutamine and 10%
bovine calf serum. Contamination of cells with mycoplasm species was
excluded by frequent PCR testing of cellular DNA with mycoplasm-spe-
cific primers (mycoplasm detection kit; American Type Culture Collec-
tion). The mAbs used in this study for cellular depletion, flow cytometric,
and/or sorting purposes comprised PE-conjugated anti-TCR V14 mAb;
FITC-conjugated anti-CD4 mAb; and PE or nonconjugated anti-CD8
mAb (all obtained from BD Biosciences). Abs used for immune precipi-
tation and immune detection included anti-CD8 mAb (UCHT-4, recog-
nizing the extracellular part of human CD8; Kordia Life Sciences) and
anti-LCK mAb (3A5, recognizing aa 54-222 of human LCK; Santa Cruz
Biotechnology). Anti-CD8 mAb (4H8; Sanquin Blood Supply Founda-
tion) was also used as a blocking reagent in cytotoxicity assays. Other
reagents used in this study were: RetroNectin (human fibronectin frag-
ments CH-296; Takara Shuzo); gp100/HLA-A2 tetramer (ProImmune);
gp100 peptide YLEPGPVTA (26); and PMA and PHA (Sigma-Aldrich).
Cloning of TCR and CD8 genes and transduction of human T
lymphocytes
The genes encoding gp100/HLA-A2-specific TCR genes (i.e.,
gp100/A2 TCR) were derived from the high-avidity CTL-296 and inserted
into the retroviral vector pBullet (26). The pBullet containing the human
CD8 transgene (termed CD8t) was described earlier (15). Using the
pBullet:CD8t as template DNA, we generated a CD8 variant mutated at
a conserved cysteine motif that is responsible for binding LCK (analogous
to CD8-MC-1/2 (28)) and LAT (23) (termed CD8tC215/7A). In short, two
endogenous cysteines (aa 215 and 217, according to sequence reference
number gi 4502688, with amino acid numbering starting at M) were tar-
geted via mutagenesis (QuikChange Site-Directed Mutagenesis; Strat-
agene) and changed into alanines using the following primers (5 to 3):
CD8 mutant forward, AGACGTGTTGCCAAAGCTCCCCGGCCT and
CD8 mutant reverse, AGGCCGGGGAGCTTTGGCAACACGTCT (with
introduced nucleotide mutations underlined). CD8tC215/7A insert was
checked by sequence analysis. The TCR, CD8t, or CD8tC215/7A genes
were introduced into anti-CD3 mAb-activated primary human T cells, as
described (26). Before gene transfer, T cells were enriched for CD4 T
cells using a depleting anti-CD8 mAb and goat anti-mouse Ig-labeled
magnetic beads (Dynal Biotech), according to the manufacturer’s instruc-
tions. CD8-negative T cells were used as recipients for TCR and CD8
genes, whereas nondepleted (bulk) T cells were used as recipients for TCR
genes only.
Immune precipitation and Western blot
T cell transductants (2.5  107 cells) expressing gp100/A2 TCR and either
CD8t or CD8tC215/7A were lysed in 10 mM Tris-Cl (pH 7.6), 150 mM
NaCl, 2 mM EDTA, and 0.5% Nonidet P-40 (Sigma-Aldrich) for 20 min
on ice in the presence of the enzyme inhibitors 50 g/ml aprotinin, 50
g/ml leupeptin, 0.2 mM PMSF, 1 mM NaVO3, and 0.5 mM NaF (all
obtained from Sigma-Aldrich). Cleared lysate was immune precipitated
with anti-CD8 mAb (UCHT-4; 1 g/ml) overnight at 4°C, followed by
protein G-Sepharose coated with rabbit anti-mouse IgG for 1 h at 4°C. The
immune precipitates were washed, loaded, and run on a 12% Tris-HCl gel
(Bio-Rad), and transferred onto polyvinylidene difluoride membranes (Bio-
Rad) under semidry conditions. The membranes were subsequently used
for immune detection with anti-LCK mAb (3A5; 2 g/ml) for 3 h at room
temperature, followed by peroxidase-labeled sheep anti-mouse IgG
(1:2500; Amersham Biosciences) for 30 min at room temperature and de-
veloped via chemiluminescence (SuperSignal West Pico Chemilumines-
cent Substrate; Pierce).
Flow cytometry of gene-modified T lymphocytes
TCR-transduced T cells were analyzed for TCR and CD8 expression by
flow cytometry using anti-TCR V14, the gp100/HLA-A2 tetramer, and/or
CD8 mAb. Viability of T cell populations was assessed by trypan blue
exclusion, and only those with a viability 90% were immunostained for
flow cytometric analysis. For immunostaining, 0.1–0.5 106 transduced T
cells were washed with ice-cold PBS containing 0.5% BSA and 0.02%
EDTA, and incubated with mAbs or tetramers on ice for 30 min. Upon
completion of the immunostainings, cells were washed again, fixed (with
1% paraformaldehyde), and analyzed on a Cytomics FC-500 flow cytom-
eter (Beckman Coulter). The dot plots or histograms represent viable T
cells gated on forward and sideward light scatter signals. Sorting was per-
formed on a FACSVantage (BD Biosciences) using peptide/MHC tetram-
ers and/or CD8 mAb. Sorted T cells were validated for transgene expres-
sion(s) (90%) and expanded in feeder plates before their testing.
Cytotoxicity assay
Cytotoxic activity of T cell transductants was routinely measured in 6-h
51Cr release assays, essentially as described (26). BLM target cells were
loaded with gp100 peptide (10 M final) for 45 min at 37°C/5% CO2
before cocultivation with effector T cells. Cytotoxicity assays were per-
formed with various E:T ratios, and in the presence of K562 cold target
cells at a 30:1 ratio over 51Cr-labeled target cells. Some cytotoxicity assays
were performed in the presence of blocking anti-CD8 mAb (10 g/ml),
added to the effector T cells 30 min before cocultivation with target cells.
Percentage of specific cytolysis, i.e., specific 51Cr release, was calculated
as described previously (29).
Cytokine production
To quantify the production of Th1- and Th2-type cytokines by TCR and/or
CD8-transduced T cells after Ag-specific stimulation, 6  104 T cells
were cultured in the presence of 2 104 tumor cells for 18 h. As a positive3 Abbreviation used in this paper: LAT, linker for activation of T cell.
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control, T cell transductants were stimulated with PHA and PMA. Super-
natants were harvested, and levels of IL-2, IL-4, IL-5, IL-10, IFN-, and
TNF- were determined via Cytokine Bead Array (Th1/Th2 CBA kit; BD
Biosciences), according to the manufacturer’ s instructions. This flow cy-
tometry-based technique allows the quantification of multiple cytokines
simultaneously.
Results
The gp100/A2 TCR is able to bind peptide/MHC and mediate
cytotoxicity independent of CD8
To analyze the function of CD8 in antitumor T cell responses, not
related to its ability to stabilize TCR-mediated binding of peptide/
MHC class I, we made use of a gp100/A2 TCR that enables T cells
to bind peptide/MHC class I in the absence of CD8 (i.e., a CD8-
independent TCR). CD8 and CD4 gp100/A2 TCR transductants
were made, as well as CD4 gp100/A2 TCR transductants with a
cointroduced CD8 transgene (termed CD8t). Fig. 1a shows high
CD8 expression in both T cell populations expressing either en-
dogenous CD8 or CD8t, but no expression of CD8 in CD4-
only T cells (upper panels). Fig. 1b demonstrates that gp100/A2
TCR-mediated binding of the relevant peptide/MHC ligand is in-
dependent of CD8. Next, the gp100-specific cytotoxic activity of
these TCR and/or CD8 transductants was analyzed (Fig. 2).
CD4 T cells transduced with gp100/A2 TCR lysed Ag-positive
melanoma cells, but did not lyse melanoma cells lacking the rel-
evant Ag. The cointroduction of CD8 did only slightly increase
the cytolytic activity of gp100/A2 TCR transductants. Preincuba-
tion of CD8 T cells with anti-CD8 mAb did neither affect the
binding of gp100/A2 tetramers (data not shown) nor the gp100-
specific cytotoxicity (Fig. 2).
CD8 inhibits production of IL-4, IL-5, and IL-10
Next, the contribution of CD8 to TCR-mediated functions was
followed up at the level of tumor-specific cytokine production. T
cells expressing either endogenous CD8 or no CD8 (i.e., CD4
T cells) produce IL-4 and IL-5 in response to gp100-positive mel-
anoma cells, especially gp100-transfected BLM cells, but also, al-
beit at lower levels, FM3 cells that natively express gp100, but not
in response to gp100-negative melanoma cells (Fig. 3a). Surpris-
ingly, the cointroduction of CD8t into CD4 TCR-transduced T
cells almost completely abolished the gp100-specific production of
both cytokines. The gp100-specific IL-10 production follows a dif-
ferent pattern. T cells expressing CD4 only, but not those express-
ing endogenous CD8, readily produce IL-10 in response to
gp100-positive melanoma cells, which again becomes down-reg-
ulated in the copresence of CD8t (Fig. 3a). The CD8-mediated
down-regulation of tumor-specific cytokine production by T cells
appears specific for IL-4, IL-5, and IL-10. Ag-specific production
of IFN- only decreased slightly, whereas production of TNF-
FIGURE 1. The gp100/A2-specific T cells do not require CD8 for
binding peptide/MHC I ligand. CD8-positive and -negative fractions of
primary human T cells were transduced with TCR genes derived from a
gp100/A2-specific CTL-296 and, in case of CD8-negative T cells (i.e.,
CD4 T cells), also a CD8t gene. T cells were subsequently sorted into
three populations with the use of PE-labeled gp100/A2 tetramer and FITC-
labeled CD8 mAb: 1) CD8 T cells expressing the TCR transgenes; 2)
CD4 T cells expressing the TCR transgenes; and 3) CD4 T cells
expressing the TCR and CD8t transgenes. These three T cell popula-
tions were validated by flow cytometry for the expression of CD4 and CD8
(a) and binding with tetramers (b). See Materials and Methods for details
on flow cytometry and sorting of T cells. Empty histograms represent stain-
ing with a nonrelated HLA-A2-binding tetramer. Data represent one of two
donors with similar results.
FIGURE 2. The gp100/A2-specific T cells do not require CD8 for
tumor-specific cytotoxicity. The T cell populations shown in Fig. 1 were
used as effector T cells in 6-h 51Cr release assays. Target cells used were
the HLA-A2-positive (but gp100-negative) melanoma cell line BLM and
the gp100 transfectant BLMgp100. Cytotoxicity assays with the Ag-posi-
tive target cells were performed in the absence and presence of a blocking
anti-CD8 mAb. See Materials and Methods for details on cytotoxicity
assays. Data are presented as means from triplicate measurements with
SEMs not exceeding 10%. Results were similar for two donors, each tested
in two separate experiments.
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and IL-2 increased because of cointroduction of CD8t into T cells
(see Fig. 3b).
CD8-mediated down-regulation of IL-4 and IL-5 production,
but not IL-10, depends on cysteine motif
To study the mechanism behind the CD8-mediated decrease in
tumor-specific production of the three Th2-type cytokines, we gen-
erated a CD8 mutant (termed CD8tC215/7A) in which two ala-
nines substitute cysteines that are normally involved in the recruit-
ment of intracellular LCK (see Fig. 4a) and LAT. CD8tC215/7A
was validated for its expression and inability to bind LCK in T
cells (Fig. 4, b and c). Flow cytometric analysis of T cells cotrans-
duced with gp100/A2 TCR and CD8tC215/7A showed that the ex-
pression of the CD8 transgene was not affected by the cysteine to
alanine mutations (compare Figs. 1a vs 4b). Coimmune precipita-
tions using an anti-CD8 Ab confirmed that CD8tC215/7A has a
decreased ability to bind LCK and allowed us to use this mutant to
analyze the role of CD8-mediated signaling in Ag-specific T cell
functions (Fig. 4c). The CD8tC215/7A did not adversely affect the
cytotoxic activity of T cells (Fig. 5). If anything, CD8tC215/7A did
slightly improve the cytotoxic ability of T cells transduced with
gp100/A2 TCR (when compared with CD8t). Next, we assessed
the effect of CD8tC215/7A on tumor-specific cytokine production
by T cells. As put forward in Fig. 6a, the CD8-mediated inhibi-
tion of tumor-specific IL-4 and IL-5 production depends on the
ability of CD8 to recruit LCK and/or LAT because the introduc-
tion of CD8tC215/7A does not inhibit the tumor-specific produc-
tion of these cytokines. The involvement of CD8-mediated sig-
nals to inhibit cytokine production appears to be restrictive in
nature, because CD8 inhibits the tumor-specific production of
IL-10 irrespective of a mutation in its cysteine motif (Fig. 6a). In
addition, CD8tC215/7A did not affect the tumor-specific produc-
tion of IFN-, TNF-, and IL-2 by T cells (Fig. 6b).
Discussion
In the present work, we demonstrate that genetic introduction of
CD8 into human CD4 T cells redirected with a high-avidity
TCR contributes to tumor-specific Th1 responses. CD4 T cells
transduced with gp100/A2-specific TCR bind peptide/MHC class I
and kill gp100-positive tumor cells, neither being further enhanced
by cointroduction of CD8t (Figs. 1 and 2). A study with another
TCR, i.e., a MAGE-A1/HLA-A1-specific TCR, shows an absolute
requirement of CD8 for both TCR-mediated binding of peptide/
MHC class I and cytotoxicity (15). Gene transfer of the latter TCR
results in cytotoxic responses toward peptide-loaded target cells
that are 2 logs less sensitive compared with the gp100/A2 TCR
used in the present study. We therefore believe that ligand-binding
properties of the TCR dictate the CD8 dependence of T cell re-
sponsiveness. The presented results are in agreement with recent
findings that high-affinity TCR:peptide/MHC interactions allow an
accumulation of activation signals over time, resulting in CTL ef-
fector functions overriding the need for CD8 engagement (30). The
observed killing of tumor cells by TCR-transduced CD4 T cells
in short-term chromium release assays points to granzyme-medi-
ated lysis as at least one of the mechanisms of killing. CD4 T
cells have previously been reported to kill in an MHC class II-
restricted and Ag-specific manner using primarily the Fas/Fas li-
gand and apoptosis-inducing pathways as well as, albeit it in gen-
eral to a lesser extent, the exocytotic pathway (31). Interestingly,
recent reports suggest that antitumor responses of TCR-transduced
CD4 T cells may require MHC class II expression on target cells
(32, 33). Cointroduction of WT1-specific TCR and CD8 genes
appeared to rescue cytotoxicity, but not cytokine production by
human Th1 cell toward naturally processed tumor Ag on MHC
class II-negative leukemia cells (T. Nishimura, unpublished obser-
vations). In another study, although using murine CD4 T cells,
the MHC class II dependence of IFN- production was shown to
FIGURE 3. CD8 transgene expression in gp100/A2-specific CD4 T cells down-regulates gp100-specific production of IL-4, IL-5, and IL-10, but not
IFN-, TNF-, and IL-2. The T cell populations shown in Fig. 1 were used as effector T cells in cytokine production assays. Effector T cells were stimulated
for 18 h at a 3:1 ratio using the following target cells: BLM, BLMgp100 (gp100/HLA-A2positive), FM3, and (gp100/HLA-A2neg) MZ2-MEL3.0. Negative
and positive controls were medium and PMA/PHA stimulations, respectively. Cell-free supernatants were harvested and tested for the following cytokines:
IL-2, IL-4, IL-5, IL-10, IFN-, and TNF- via Cytometric Bead Array. a, The results for IL-4, IL-5, and IL-10 are given; b, the results for the other three
cytokines are given. Cytokine levels exceeding 6000 pg/ml (shown as out of range) were as follows (responses to either BLMgp100 or FM3 cells separated
by a slash and in ng/ml). IFN-  CD8: 89.6/17.0; CD4: 134.4/90.2; CD4  CD8t: 107.5/59.2. TNF-  CD8: 6.3; CD4: 18.8; CD4  CD8t: 32.8.
IL-5  CD8: 24.7/6.5; CD4: 11.0. Data are presented as means from triplicate measurements with SEMs not exceeding 10%. Results were similar for two
donors, each tested once.
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be relieved by cointroduction of CD8 (33). Our own data do not
point to a significant contribution of MHC class II to the respon-
siveness of TCR-transduced CD4 T cells. First, target cells used
in the present study were negative for MHC class II (data not
shown), but did not prevent TCR-transduced CD4 T cells to both
kill and produce cytokines in response to gp100 Ag in the absence
of CD8. Second, MAGE-A1-positive target cells (such as MZ2-
MEL2.2 and 3.0) were clearly positive for MHC class II, and were
only able to elicit both cytotoxicity and cytokine production by
TCR-transduced CD4 T cells in the presence of CD8 (15). To
address the contribution of CD4 signaling to CD8-dependent T
cell responsiveness more directly, experiments to block MHC class
II in the context of MAGE-A1/HLA-A1-redirected CD4 T cells
are currently ongoing in our laboratory.
In this study, CD4 T cells show CD8-independent tumor-spe-
cific production of both Th1- and Th2-type cytokines, possibly due
to prominent TCR oligomerization and formation of stable im-
mune synapses directed by the high-avidity gp100/A2 TCR. The
genetic introduction of CD8 into CD4 T cells drastically down-
regulates the Ag-specific production of IL-4, IL-5, and IL-10 (Fig.
3), but not other Th2-type cytokines such as IL-6, IL-13, and IL-15
FIGURE 4. Generation and validation of CD8 mutant, termed
CD8tC215/7A. CD8t was mutated at the cysteine motif (CKCP) by chang-
ing two cysteines into alanines, yielding CD8tC215/7A (a). Mutation of the
two cysteines (aa 215 and 217 according to sequence reference number gi
4502688, with amino acid numbering starting at M) prevents binding of
p56LCK through its N-terminal aa 10–32 (indicated as f) (28). Structural
domains of both CD8 and p56LCK are indicated in a. Surface expression
of this mutant was validated by flow cytometric analysis of CD4 human
T cells either mock transduced or transduced with and sorted for both the
gp100/A2 TCR and CD8tC215/7A (b). Upper panels, Show expressions of
CD4 and CD8, whereas the lower panels depict binding to tetramer. Ex-
pression profiles are similar to those using the CD8t (see Fig. 1). c, The
decreased ability of CD8tC215/7A to recruit LCK is demonstrated by co-
immune precipitations. CD4 T cells expressing either CD8t or
CD8tC215/7A, while growing at log phase under normal culture conditions,
were lysed and used for CD8 immune precipitations (UCHT-4 mAb).
Immune precipitates were loaded on a 12% Tris-HCl gel, blotted onto
polyvinylidene difluoride membranes, and immune detected using anti-
LCK mAb (3A5).
FIGURE 5. CD8tC215/7A does not adversely affect tumor-specific T
cell cytotoxicity. Three T cell populations expressing gp100/A2 TCR and
either no CD8, CD8t, or CD8tC215/7A (see Figs. 1 and 4 for the cor-
responding flow cytometry data) were used as effector T cells in 51Cr re-
lease assays. See legend to Fig. 2 for details on the use of target cells and
assay conditions. Data are presented as means from triplicate measure-
ments with SEMs not exceeding 10%. Results were similar for two donors,
each tested in two separate experiments.
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(data not shown). The down-regulatory effects of CD8 may be
typical for IL-4, IL-5, and IL-10, and may adversely affect a hu-
moral and eosinophilic response, and is likely to promote a Th1-
type response (by releasing a negative feedback loop via IL-10)
(34). CD8 may facilitate, albeit via different mechanisms, tumor-
specific Th1-type responses in CD4 T cells redirected with either
a CD8-dependent TCR specific for MAGE-A1/HLA-A1 (up-reg-
ulation of Th1-type cytokine production (15)) or a CD8-indepen-
dent TCR specific for gp100/A2 (down-regulation of the Th2-type
cytokines IL-4, IL-5, and IL-10). The recent observation that hu-
man CD4 T cells retargeted with another CD8-independent TCR
(i.e., p53/HLA-A2-specific TCR), but not a CD8-dependent TCR
(i.e., murine double-minute 2 oncoprotein/HLA-A2-specific TCR),
is also able to produce Th1-type cytokines (Th2-type cytokines
were not tested) following Ag-specific stimulation (24), suggests
that the Th1-inducing effect from introduced CD8 into TCR-
modified CD4 T cells may not be restricted to certain TCRs.
CD8 containing a mutated LCK and LAT binding domain,
termed CD8tC215/7A, enabled analysis of the CD8-mediated sig-
naling with respect to down-regulation of IL-4, IL-5, and IL-10
production. The CD8 mutant expresses well, does not affect the
cytotoxic activity of T cells, and shows reduced binding to LCK
(binding to LAT was not tested) (Figs. 4 and 5). The introduced
cysteine to alanine mutations in CD8 do, in contrast to CD4, not
completely abolish its association with LCK, thereby confirming
the initial biochemical characterization of this CD8 mutant (28).
The mutational effect, however, is reported to drastically decrease
CD8-associated kinase activity (28). Genetic introduction of
CD8tC215/7A in our T cells does not adversely affect the tumor-
specific production of IFN-, TNF-, and IL-2, but points to a
central involvement of LCK and/or LAT to CD8-mediated down-
regulation of the tumor-specific production of IL-4 and IL-5, but
not IL-10 (Fig. 6). In fact, both LCK and LAT have been reported
to mediate signals leading to down-regulated production of Th2-
type cytokines in CD4 T cells. First, LCK-deficient T cells or
treatment of T cells with a kinase-dead LCK result in elevated
production of Th2-type cytokines (35, 36). Second, compromised
LCK may result in insufficient affinity maturation of LFA-1, and
thereby lead to a Th2 phenotype (activated LFA-1 is normally able
to inhibit STAT6-dependent up-regulation of GATA-3 and Th2-
type cytokines; for review see Ref. 37). In this respect, it is par-
ticularly interesting that LFA-1-mediated adhesion is reported to
be a critical element for tumor eradication by adoptive transfer of
Th1, but not Th2 cells (38). Third, LCK is capable of tyrosine
phosphorylating and activating Jaks as well as STAT factors (39,
40), and may either via the Jak-STAT pathway or other means
affect the production of the transcription factors T-bet and
GATA-3, resulting in a decreased production of IL-4 and IL-5.
Fourth, members of the Tec family of protein kinases can be ac-
tivated through phosphorylation by LCK and are subsequently able
to regulate Th cell differentiation (41). For instance, IL-2 tyrosine
kinase may skew Th cells toward a Th2 phenotype, possibly
through interactions with LAT and activation of phospholipase
C-1 (41). Finally, mutating one of LAT’s tyrosines (Y136 in
mice, equivalent to Y132 in humans) results in chronic production
of large amounts of Th2-type cytokines (42). The Y136 mutation
selectively eliminates binding of phospholipase C-1, thereby
compromising a calcium flux, pointing to a negative effect from
intracellular calcium on IL-4 and IL-5 production.
It is noteworthy that the effects of CD8-mediated signaling on
IL-4, IL-5, and IL-10 production appear not to hold true for en-
dogenous CD8 (see Fig. 3). We postulate that the apparent dif-
ferences between exogenous and endogenous CD8 are caused by
differential routes of LCK and possibly LAT recruitment to the
TCR complex and signaling pathways that may exist between
CD4 and CD8 T cell subsets. In example, lipid rafts from
CD8 T cells, but not CD4 T cells, already contain LCK before
activation and do not polarize to the T cell:target cell contact site
(43). In addition, CD8 (not present on TCR/CD8-transduced
CD4 T cells) has an intracellular palmitoylation signal that is
reported to enable recruitment of TCR:CD8 complexes to lipid
rafts (44), and enhances the CD8-associated binding and activa-
tion of LCK (28) as well as LAT (23). Lastly, activation of com-
ponents upstream of GATA3, such as STAT6, is controlled dif-
ferently in CD4 vs CD8 T cells (45). The exact mechanisms
downstream of CD8-associated LCK (or LAT) that affect the
Ag-specific production of IL-4 and IL-5 on the one hand and IL-10
in contrast are currently under investigation. In this respect, it
should be noted that presented data reflect bulk cultures of T cells,
and that one cannot exclude the possibility that at a single cell level
responses may operate differently.
CD4 T cells producing Th1-type cytokines have been reported
to display potent antitumor activities in T cell transfer studies (12,
FIGURE 6. CD8-mediated down-regulation of
gp100-specific production of IL-4 and IL-5, but not IL-
10, depends on the ability of CD8 to mediate intracel-
lular signaling. The T cell populations shown in Fig. 5
were used in cytokine production assays. Conditions are
as described in the legend to Fig. 3. Cell-free superna-
tants were harvested and tested for cytokines via Cyto-
metric Bead Array. a, The results for IL-4, IL-5, and
IL-10 are given; b, the results for the other three cyto-
kines are given. Cytokine levels exceeding 6000 pg/ml
(shown as out of range) were as follows (responses to
either BLMgp100 or FM3 cells separated by a slash and
in ng/ml). IFN-  CD4: 134.4/90.2; CD4  CD8t:
107.5/59.2; CD4  CD8tC215/7A: 80.6/48.3. TNF- 
CD4CD8tC215/7A: 32.2. IL-5CD4CD8tC215/7A:
6.3. Data are presented as means from triplicate measure-
ments with SEMs not exceeding 10%. Results were similar
for two donors, each tested once.
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38, 46, 47). For instance, OVA-specific murine CD4 T cells pro-
ducing Th1-type cytokines, but not those producing Th2-type cy-
tokines, eradicate (OVA-positive) tumors in T cell transfer studies
by induction of OVA-specific CD8 T cells and maintenance of
CTL memory (38). In addition, CD4 T cells retargeted with an
Ab-based receptor and producing Th1-type cytokines display an-
titumor effects in xenotransplantation models using tumors posi-
tive for either human CEA or ErbB2 and synergize with CD8 T
cells retargeted with the same receptor (46, 48). The introduction
of local help to CTL by Th cells, preferably producing Th1-type
cytokines, is considered crucial to overcome immunosuppression
in tumor-bearing hosts. In this study, we demonstrate that genetic
introduction of CD8 into CD4 T cells induces the generation of
tumor-specific Th1 cells and may improve efficacy of TCR gene
therapy to treat cancers. Successful development of this strategy
also warrants studies into safety aspects. For instance, the risk of
autoimmunity by activation of “ignorant” autoreactive T cells that
are triggered by the introduced TCR may be affected by strategies
that impact TCR signaling such as the one presented in this study.
In our opinion, however, CD8 may not get recruited to MHC
class II-restricted TCRs, making it unlikely that this coreceptor
aids the endogenous TCR signaling of CD4 T cells. Another
safety aspect is possible mispairing of TCR chains (i.e., formation
of new TCR heterodimers comprising both introduced and en-
dogenous TCR chains) that may again result in autoimmune reac-
tions. To address TCR mispairing, our laboratory pioneered the
development of various alternative formats for MHC-restricted re-
ceptors (49). Finally, insertional mutagenesis as a consequence of
retroviral gene transfer may represent a serious safety issue, as it
has already led to a third case of leukemia in the treatment of
X-SCID with progenitor cells transduced with common -chain
(50). Although insertional mutagenesis needs to be addressed in
gene transfer studies using integrating viruses, it is important to
state that, to date, in contrast to hemopoietic stem cells, there is no
evidence of adverse effects of retroviral gene transfer into mature
T cells.
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